Last edition
News about "Gene-Editing Partnership with Seamless Therapeutic"
Eli Lilly Enters USD 1.12 Billion Gene-Editing Partnership with Seamless Therapeutics
Eli Lilly and Company has entered into a strategic collaboration worth up to USD 1.12 billion with private gene-editing company Seamless Therapeutics to develop next-generation therapies for hearing loss. The agreement strengthens Lilly’s push into genetic medicines and expands its pipeline beyond its core diabetes and obesity treatments.
Gene-Editing Partnership With Seamless Therapeutic | 29/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy